-- TED Today, a daily, online video series
shares motivational stories from the TED community and useful
resources to help people along their TED journey --
Today marks the start of the first-ever Thyroid Eye Disease
(TED) Awareness Week, taking place from Nov. 16 to Nov. 20, to
increase awareness of TED – a serious, progressive, and
vision-threatening rare autoimmune disease. TED Awareness Week has
been established through a collaboration among Horizon Therapeutics
and advocacy organizations including the American Autoimmune
Related Diseases Association (AARDA), the Alliance for Eye and
Vision Research (AEVR), the Graves’ Disease and Thyroid Foundation
(GDATF), and Prevent Blindness. Each organization is committed to
the TED community and has a variety of activities planned,
including the sharing of educational information and resources
throughout the week.
While TED most commonly occurs in people with Graves’ disease,
it is a separate disease that can occur without the presence of
Graves’ disease and requires a different treatment approach.1,2,3
Symptoms may include eye grittiness, redness, swelling and pain,
light sensitivity, eye bulging, double vision and facial
disfigurement.1,2 TED is a rare disease that is often misunderstood
and misdiagnosed, so it is critical to educate people who are at
risk for TED so that they can better recognize the symptoms, know
how to find a TED Specialist, and feel empowered to get the support
and care they need. It is also critical to educate the public about
TED so that everyone can be supportive of those impacted by this
disease.
To commemorate the first TED Awareness Week, Horizon is
launching TED Today, a daily, online talk show designed to educate,
empower and entertain viewers by delivering valuable information
from a variety of perspectives, including TED patients, caregivers,
and specialists. TED Today will be posted to the Listen to Your
Eyes Facebook community page each morning during TED Awareness
Week. TED Today will focus on a range of topics relevant to the TED
community, including the critical role of the caregiver, building a
strong care team, learning to be your own best advocate, and
maintaining positive mental health while living with TED. TED Today
will also feature patient advocacy organization interviews and
information advising patients and caregivers where they can find
important online resources, including a tool for tracking symptoms
and a TED Specialist Finder.
“When I was diagnosed more than five years ago, I didn’t know
where to turn and felt isolated living with a rare disease,” said
Beatriz Mallory, Thyroid Eye Disease patient advocate and co-host
of TED Today. “I’m honored to participate in this important event,
share my experience and hear the inspirational stories of others. I
hope that our actions to educate and raise awareness of Thyroid Eye
Disease this week and beyond will help motivate people who are
living with or are at risk for developing this debilitating disease
to advocate for themselves, find a community, and get the support
and care that they deserve.”
“At Horizon, we are focused on addressing the needs of patients
living with rare diseases, including Thyroid Eye Disease, not only
with therapies, but also by providing tools and resources to help
patients actively manage their disease and improve their
experience,” said Tim Walbert, chairman, president and chief
executive officer, Horizon. “Through our collaboration with AARDA,
AEVR, GDATF and Prevent Blindness, we are encouraging patients,
physicians and advocates to continue sharing personal stories and
educating about Thyroid Eye Disease with the hope of shedding light
on this truly life-altering disease. We are proud to support the
first Thyroid Eye Disease Awareness Week and look forward to
establishing it as an annual milestone.”
Find additional information about TED at ThyroidEyes.com, and
visit the AARDA, AEVR, GDATF and Prevent Blindness websites for
more information about our advocacy collaborators.
About Thyroid Eye Disease (TED)
TED is most often seen in patients with Graves’ disease –
affecting up to half of people with Graves’ – but it is a distinct
disease that requires separate treatment.1,2,3 A diagnosis of TED
may even precede a finding of Graves’ and can serve as an early
warning sign of future thyroid dysfunction.4 TED can also occur in
Hashimoto’s hypothyroidism or even in patients with neither
diagnosis.3 Common symptoms of TED include light sensitivity, eye
grittiness, bulging eyes and double vision, among others – all of
which can reduce a person’s independence, ability to work and
self-confidence.5,6 In fact, people living with TED often
experience long-term functional, psychosocial and economic burdens,
including inability to work and perform activities of daily
living.6,7
About AARDA
American Autoimmune Related Diseases Association (AARDA) is the
nation’s only nonprofit organization dedicated to bringing a
national focus to autoimmunity as a category of disease and a major
women’s health issue, promoting public awareness, patient education
and support, advocacy, and collaborative research efforts to
promote better treatments and a cure for all autoimmune diseases.
For more information, visit www.aarda.org. Follow us on social
media: Facebook (www.facebook.com/Autoimmunity), Twitter
(@AARDATweets), Instagram (@autoimmune_diseases), and YouTube
(www.youtube.com/AARDATube).
About AEVR
The Alliance for Eye and Vision Research (AEVR), a 501(c)3
non-profit foundation, conducts sustained educational efforts about
the value of federally funded vision research primarily through its
Congressionally recognized Decade of Vision (DOV) 2010-2020
Initiative. Within the DOV, AEVR conducts Congressional Briefings,
including a November 19, 2020, virtual global Briefing that
recognizes the first annual TED Awareness Week. Visit the Web site
at www.eyeresearch.org.
About the Graves’ Disease and Thyroid Foundation
The Graves’ Disease and Thyroid Foundation (GDATF) is the
leading source of help and hope for people with Graves’ disease and
other thyroid related disorders. The organization provides
education and support for patients, family members, caregivers,
friends and healthcare professionals. GDATF has helped thousands of
patients better understand the symptoms and treatment programs for
Graves' disease. The Foundation is a 501 C(3) tax-exempt non-profit
international charitable organization. For more information visit
www.GDATF.org, and find us on Twitter (@GDATF), Facebook and
Instagram.
About Prevent Blindness
Founded in 1908, Prevent Blindness is the nation's leading
volunteer eye health and safety organization dedicated to fighting
blindness and saving sight. Focused on promoting a continuum of
vision care, Prevent Blindness touches the lives of millions of
people each year through public and professional education,
advocacy, certified vision screening and training, community and
patient service programs and research. These services are made
possible through the generous support of the American public.
Together with a network of affiliates, Prevent Blindness is
committed to eliminating preventable blindness in America. For more
information, or to make a contribution to the sight-saving fund,
call 1-800-331-2020. Or, visit us on the Web at
preventblindness.org or facebook.com/preventblindness.
About Horizon
Horizon is focused on researching, developing and
commercializing medicines that address critical needs for people
impacted by rare and rheumatic diseases. Our pipeline is
purposeful: we apply scientific expertise and courage to bring
clinically meaningful therapies to patients. We believe science and
compassion must work together to transform lives. For more
information on how we go to incredible lengths to impact lives,
please visit www.horizontherapeutics.com and follow us on Twitter,
LinkedIn, Instagram and Facebook.
References
- Lazarus JH. Epidemiology of Graves’ orbitopathy (GO) and
relationship with thyroid disease. Best Pract Res Clin Endocrinol
Metab. 2012;26(3):273-279.
- Smith TJ, Hegedüs L. Graves’ Disease. N Engl J Med.
2016;375(16):1552-1565.
- Eckstein AK, Losch C, Glowacka D, et al. Euthyroid and
primarily hypothyroid patients develop milder and significantly
more asymmetrical Graves’ ophthalmopathy. Br J Ophthalmol.
2009;93(8):1052-1056.
- McAlinden C. An overview of thyroid eye disease. Eye Vis
(Lond). 2014;1:9. doi:10.1186/s40662-014-0009-8.
- Barrio-Barrio J, Sabater AL, Bonet-Farriol E,
Velazquez-Villoria A, Galofre JC. Graves’ Ophthalmopathy: VISA
versus EUGOGO Classification, Assessment, and Management. Journal
of Ophthalmology. 2015:1-16.
- Ponto KA, Pitz S, Pfeiffer N, Hommel G, Weber MM, Kahaly GJ.
Quality of life and occupational disability in endocrine
orbitopathy. Dtsch Arztebl Int. 2009;106:283-299.
- Ponto KA, Merkesdal S, Hommel G, Pitz S, Pfeiffer N, Kahaly GJ.
Public health relevance of Graves’ orbitopathy. Journal of Clinical
Endocrinology & Metabolism. 2013;98:145-152.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201116005121/en/
U.S. Media Contacts: Rachel Vann Director, Product
Communications media@horizontherapeutics.com Maggie
Fairchild Senior Manager, Product Communications
media@horizontherapeutics.com
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Therapeutics Pub... (NASDAQ:HZNP)
Historical Stock Chart
From May 2023 to May 2024